Bailey, T STakács, RTinahones, F JRao, P VTsoukas, G MThomsen, A BKaltoft, M SMaislos, M2023-01-252023-01-252016-09-14http://hdl.handle.net/10668/10244To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin. A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint. Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54%; estimated mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; p  Subjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/GLP-1 receptor agonistliraglutidesitagliptintype 2 diabetesAdultAgedAged, 80 and overAsiaBlood GlucoseBody WeightDiabetes Mellitus, Type 2Double-Blind MethodDrug SubstitutionDrug Therapy, CombinationEuropeFemaleGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsLiraglutideMaleMetforminMiddle AgedNauseaNorth AmericaSitagliptin PhosphateTreatment Outcomeresearch article27381275open access10.1111/dom.127361463-1326PMC5129465https://doi.org/10.1111/dom.12736https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129465/pdf